Medchemexpress LLC N-hydroxy-4-((quinolin-8-ylamino)methyl)benzamide | 2151853-97-1 | 99.8% | 293.32 g/mol | C17H15N3O2 | 25MG

Supplier:  Medchemexpress LLC HY12397625MG

MPT0G211 is a potent, orally active, and selective histone deacetylase 6 (HDAC6) inhibitor used for preclinical research. It exhibits sub-nanomolar potency against HDAC6 (IC50 = 0.291 nM), strong selectivity over other HDAC isoforms, and is reported to penetrate the blood-brain barrier. Reported activities include reduction of tau phosphorylation and improvement of cognitive deficits in Alzheimer's disease models, along with anti-metastatic, neuroprotective, and anticancer effects.

• Potent HDAC6 inhibition (IC50 = 0.291 nM)
• >1,000-fold selectivity for HDAC6 versus other HDAC isoforms
• Orally active with reported blood-brain barrier penetration
• Demonstrated reduction of tau phosphorylation in disease models
• Reported cognitive benefit in Alzheimer's disease model studies
• High reported purity suitable for research use (≈99.8%)
• Available in small research pack sizes for in vitro and in vivo studies

Catalog No. 50-002-36755